Recent Quotes (30 days)

You have no recent quotes
chg | %

GTx, Inc.  

(Public, NASDAQ:GTXI)   Watch this stock  
Find more results for GTXI
+0.35 (2.96%)
After Hours: 12.16 0.00 (0.00%)
Jan. 16, 4:01p.m. EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.80 - 12.20
52 week 2.73 - 13.35
Open 11.81
Vol / Avg. 76,194.00/46,902.00
Mkt cap 261.95M
P/E     -
Div/yield     -
EPS -1.75
Shares 21.54M
Beta 1.77
Inst. own 22%
Mar. 13, 2018
Q4 2017 GTX Inc Earnings Release (Estimated) - 9:30a.m. EDT - Add to calendar
Nov. 15, 2017
GTX Inc at Stifel Healthcare Conference
Nov. 14, 2017
Q3 2017 GTX Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep. '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -98.13% -62.70%
Return on average equity -123.92% -162.98%
Employees 26 -
CDP Score - -


175 Toyota Plz Fl 7
MEMPHIS, TN 38103-5601
United States - Map
+1-901-2718622 (Phone)
+1-901-8448075 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

Officers and directors

Robert James Wills Ph.D. Executive Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Marc S. Hanover Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Jason T. Shackelford Senior Director, Accounting and Corporate Controller, and Principal Financial and Accounting Officer
Age: 39
Bio & Compensation  - Reuters
Henry P. Doggrell Sr. Vice President, Chief Legal Officer, Secretary
Age: 66
Bio & Compensation  - Reuters
Diane C Young M.D. Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Joseph R. Hyde III Lead Director
Age: 74
Bio & Compensation  - Reuters
Garry Neil M.D. Director
Bio & Compensation  - Reuters
Michael G. Carter M.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
J. Kenneth Glass Independent Director
Age: 68
Bio & Compensation  - Reuters
Kenneth S. Robinson M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters